Skip to main content
. 2020 Apr 9;25(3):e326–e336. doi: 10.4317/medoral.23324

Table 4. Meta-analysis results of the incidences and prognoses of MRONJ associated with zoledronic acid and Denosumab.

graphic file with name medoral-25-e326-t004.jpg